L-002 | CAS# 321695-57-2 | p300 histone acyltransferase inhibitor

MedKoo Cat#: 574767 | Name: L-002

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

L-002 is an inhibitor of p300 histone acyltransferase (KAT3B). L-002 also inhibits acetylation of histones and p53 and suppresses STAT3 activation. In vivo, L-002 potently suppressed tumor growth of TNBC cell line MDA-MB-468 xenografts.

Chemical Structure

L-002

CAS#321695-57-2

Theoretical Analysis

MedKoo Cat#: 574767

Name: L-002

CAS#: 321695-57-2

Chemical Formula: C15H15NO5S

Exact Mass: 321.0671

Molecular Weight: 321.35

Elemental Analysis: C, 56.07; H, 4.71; N, 4.36; O, 24.89; S, 9.98

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 285.00	2 Weeks
50mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

L-002, L 002, L002; p300/CBP Inhibitor VI; NSC 764414

IUPAC/Chemical Name

2,6-dimethyl-2,5-cyclohexadiene-1,4-dione 4-[O-[(4-methoxyphenyl)sulfonyl]oxime]

InChi Key

VEWFTYOFWIXCIO-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H15NO5S/c1-10-8-12(9-11(2)15(10)17)16-21-22(18,19)14-6-4-13(20-3)5-7-14/h4-9H,1-3H3

SMILES Code

COC1=CC=C(S(O/N=C2C=C(C)C(C(C)=C\2)=O)(=O)=O)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

L002 is a potent, cell permeable, reversible and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM.

In vitro activity:

Among the NCI-60 panel of cancer cell lines, leukemia and lymphoma cell lines were extremely sensitive to L002, whereas it is toxic to only a limited number of cell lines derived from solid tumors. Notably, breast cancer cell lines, especially those derived from TNBC, were highly susceptible to L002. Reference: Mol Cancer Ther. 2013 May;12(5):610-20. https://pubmed.ncbi.nlm.nih.gov/23625935/

In vivo activity:

Treatment of hypertensive mice with ATp300-specific small molecule inhibitor L002 or C646 reverses hypertension-induced left ventricular hypertrophy, cardiac fibrosis and diastolic dysfunction, without reducing elevated blood pressures. Biochemically, treatment with L002 and C646 also reverse hypertension-induced histone acetylation and myofibroblast differentiation in murine ventricles. Reference: J Cell Mol Med. 2019 Apr;23(4):3026-3031. https://pubmed.ncbi.nlm.nih.gov/30710427/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	93.36
	DMSO	52.2	162.34
	DMSO:PBS (pH 7.2) (1:2)	0.3	0.78
	Ethanol	2.5	7.78

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 321.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Rai R, Verma SK, Kim D, Ramirez V, Lux E, Li C, Sahoo S, Wilsbacher LD, Vaughan DE, Quaggin SE, Ghosh AK. A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis. Epigenetics. 2017;12(11):1004-1013. doi: 10.1080/15592294.2017.1370173. Epub 2017 Dec 6. PMID: 28933600; PMCID: PMC5788418. 2. Yang H, Pinello CE, Luo J, Li D, Wang Y, Zhao LY, Jahn SC, Saldanha SA, Chase P, Planck J, Geary KR, Ma H, Law BK, Roush WR, Hodder P, Liao D. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Mol Cancer Ther. 2013 May;12(5):610-20. doi: 10.1158/1535-7163.MCT-12-0930. Epub 2013 Apr 26. Erratum in: Mol Cancer Ther. 2013 Aug;12(8):1688. Chase, Peter [added]. PMID: 23625935; PMCID: PMC3651759. 3. Rai R, Sun T, Ramirez V, Lux E, Eren M, Vaughan DE, Ghosh AK. Acetyltransferase p300 inhibitor reverses hypertension-induced cardiac fibrosis. J Cell Mol Med. 2019 Apr;23(4):3026-3031. doi: 10.1111/jcmm.14162. Epub 2019 Feb 1. PMID: 30710427; PMCID: PMC6433695. 4. Rai R, Verma SK, Kim D, Ramirez V, Lux E, Li C, Sahoo S, Wilsbacher LD, Vaughan DE, Quaggin SE, Ghosh AK. A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis. Epigenetics. 2017;12(11):1004-1013. doi: 10.1080/15592294.2017.1370173. Epub 2017 Dec 6. PMID: 28933600; PMCID: PMC5788418.

In vitro protocol:

In vivo protocol:

1. Rai R, Sun T, Ramirez V, Lux E, Eren M, Vaughan DE, Ghosh AK. Acetyltransferase p300 inhibitor reverses hypertension-induced cardiac fibrosis. J Cell Mol Med. 2019 Apr;23(4):3026-3031. doi: 10.1111/jcmm.14162. Epub 2019 Feb 1. PMID: 30710427; PMCID: PMC6433695. 2. Rai R, Verma SK, Kim D, Ramirez V, Lux E, Li C, Sahoo S, Wilsbacher LD, Vaughan DE, Quaggin SE, Ghosh AK. A novel acetyltransferase p300 inhibitor ameliorates hypertension-associated cardio-renal fibrosis. Epigenetics. 2017;12(11):1004-1013. doi: 10.1080/15592294.2017.1370173. Epub 2017 Dec 6. PMID: 28933600; PMCID: PMC5788418.

1. Yang, H., Pinello, C.E., Luo, J., et al. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Molecular Cancer Therapeutics 12(5), 610-620 (2013).